1-Formyl-LSD
 | |
| File:1F-LSD 3D.png | |
| Clinical data | |
|---|---|
| Other names | 1-Formyl-LSD; 1-Formyl-N,N-diethyllysergamide; N,N-Diethyl-1-formyl-6-methyl-9,10-didehydroergoline-8β-carboxamide; 1F-LSD |
| Routes of administration | Oral; Sublingual |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C21H25N3O2 |
| Molar mass | 351.450 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
1-Formyl-LSD, also known as 1-formyl-N,N-diethyllysergamide and sometimes referred to as 1F-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2] It is the 1-formyl derivative of LSD.[1][2][3]
Another drug, 1‐(furan‐2‐carbonyl)‐LSD (SYN-L-005), has also been referred to as "1F-LSD".[3]
Use and effects
[edit | edit source]The drug is assumed to act as a prodrug of LSD.[1] It produces psychedelic effects in humans similarly to LSD.[2] Effective doses have been reported to be 100 to 150 μg orally or sublingually.[2] Very little is known about the pharmacology and properties of 1-formyl-LSD.[1]
Interactions
[edit | edit source]History
[edit | edit source]1-Formyl-LSD was first described in the scientific literature by 2021.[2] It first emerged as a novel designer drug online in January 2019.[1][2]
See also
[edit | edit source]References
[edit | edit source]- ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d e f Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).